Patient ID | Median dose/cycle of induction temozolamide (mg) first 4 cycles | No. vaccinations | Median no. of cells administered 106(range) | DTH Best response after 4 or more vaccinations L/H KLH | Vitiligo | Clinical response | Response duration (months) | OS (months) | After vaccination treatments | |
---|---|---|---|---|---|---|---|---|---|---|
28 | 1400 | 12 | 12.6 | +++ | +++ | - | SD | 9 | 12 | None |
(11.5–17) | ||||||||||
29 | 1400 first 2 cycles, 700 last 2 cycles | 4 | 7.7 | – | – | – | PD | 3 | None | |
(5.4–8.6) | ||||||||||
30 | 1400 | 5 | 11,9 | – | – | – | PD | 6 | None | |
(11.5–14) | ||||||||||
31 | 1400 | 8 | 12.6 | – | – | – | SD | 4 | 7 | None |
(11.1–15.3) | ||||||||||
32 | 1400 first 3 cycles, 700 last cycle | 5 | 8.5 | – | – | – | PD | 6 | None | |
(7.5–10) | ||||||||||
33 | 1400 | 8 | 8.8 | +++ | +++ | + | SD | 4 | 12 | BIOCT |
(4.9–10) | ||||||||||
34 | 1400 | 6 | 10.1 | – | – | – | PD | 14 | None | |
(6.9–14.5) | ||||||||||
35 | 1400 | 17 | 9.4 | ++ | – | – | SD | 10 | 36+ | antiCTLA4Ab |
(6.5–10.8) | ||||||||||
36 | 1400 | 6 | 9.8 | + | + | – | SD | 9 | 41+ | antiCTLA4Ab |
(8.3–13.9) | ||||||||||
37 | 1400 first cycle, 700 last 3 cycles | 17 | 7.8 | ++ | – | – | SD | 4 | 16 | None |
(5.7–10) | ||||||||||
38 | 1400 | 11 | 9.3 | – | + | – | PD | 12 | None | |
(8.1–10.8) | ||||||||||
39 | 1400 | 5 | 10 | – | – | – | PD | 7 | None | |
(10–10) | ||||||||||
40 | 1400 | 5 | 11.3 | – | – | – | PD | 4 | None | |
(10–15) | ||||||||||
41 | 700 | 10 | 9.3 | – | +++ | – | PR | 6 | 14 | None |
(5.8–10) | ||||||||||
42 | 700 | 4 | 10 | – | – | – | PD | 4 | None | |
(10–10) | ||||||||||
43 | 700 | 5 | 10 | + | + | – | PD | 8 | None | |
(9.6–13.8) | ||||||||||
44 | 700 | 7 | 10 | – | + | – | PD | 10 | antiCTLA4Ab | |
(10–10) |